ATS View
한국어

D&D Pharmatech KRX:347850KOSDAQ

디앤디파마텍 · Korean news coverage and regulatory filings, organized.

한국어
Articles, 24h0
Articles, 7 days3
DART filings, 7 days0
Articles tracked3since Sep 11

In Q2 2026, D&D Pharmatech reported revenue of ₩662m, down 28.4% year on year, and an operating loss of ₩9.9bn. D&D Pharmatech (디앤디파마텍) appeared in 3 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Sep 11 with 2 articles. The most common catalyst was tech & capacity (2).

D&D Pharmatech quarterly results consolidated, KRW

QuarterRevenueYoYOperating profitNet income
Q2 2026₩662m-28.4%−₩9.9bn−₩7.8bn
Q1 2026₩129m-90.9%−₩11.1bn−₩10.1bn
Q4 2025 derived₩990m-80.4%−₩10.4bn₩1.9bn
Q3 2025₩969m-50.0%−₩6.2bn−₩5.8bn
Q2 2025₩925m-60.1%−₩8.1bn−₩10.0bn
Q1 2025₩1.4bn-32.8%−₩9.3bn−₩10.1bn
Q4 2024 derived₩5.1bn+180.0%−₩6.9bn−₩9.8bn
Q3 2024₩1.9bn-72.3%−₩7.0bn−₩8.1bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.

D&D Pharmatech top stories 2 weeks, by number of outlets

  1. 1
    디앤디파마텍, 섬유화증 치료제 'TLY012' 일본 물질특허 등록 결정
    2 outlets · 2 articlesFirst report Sep 11 13:37 프라임경제New technology
  2. 2
    디앤디파마텍 "섬유화증 치료제, 日 물질특허"
    1 outlets · 1 articlesFirst report Sep 13 11:01 뉴시스경제

Latest D&D Pharmatech news Korean headlines